Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This multimodal analgesic regimen is a combination of three distinct pharmaceutical agents used as a standard-of-care comparator in clinical trials conducted by Beijing Tiantan Hospital for the management of acute and subacute zoster-associated pain (herpes zoster). The regimen consists of **pregabalin**, a calcium channel alpha-2-delta ligand that modulates the release of excitatory neurotransmitters; **celecoxib**, a selective cyclooxygenase-2 (COX-2) inhibitor that reduces inflammatory prostaglandin synthesis; and **tramadol**, a centrally acting opioid agonist that also inhibits the reuptake of serotonin and norepinephrine. This combination is designed to target multiple pain pathways simultaneously, addressing both the neuropathic and inflammatory components of pain associated with varicella-zoster virus reactivation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pregabalin + celecoxib + tramadol.